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Abstract  
Dual-acting kappa opioid receptor (KOR) agonist and mu opioid receptor (MOR) partial agonist 
ligands have been put forward as potential treatment agents for cocaine and other psychostimulant 
abuse. Members of the orvinol series of ligands are known for their high binding affinity to both 
KOR and MOR but efficacy at the individual receptors has not been thoroughly evaluated. In this 
study, it is shown that a predictive model for efficacy at KOR can be derived, with efficacy being 
controlled by the length of the group attached to C20 and by the introduction of branching into the 
side chain.  In vivo evaluation of two ligands with the desired in vitro profile confirms both display 
KOR, and to a lesser extent MOR, activity in an analgesic assay suggesting that, in this series, in 
vitro measures of efficacy using the [
35
S]GTPS assay are predictive of the in vivo profile. 
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Introduction 
The continuing illicit use of psychoactive substances, with the resulting health and social 
consequences, emphasizes the need for improved pharmacotherapies for drug abuse.  Treatments 
for opiate abuse, such as methadone and buprenorphine (1n), are available and have proven 
successful against a range of addict populations.  However there are no such approved 
pharmacotherapies for cocaine abuse, though a wide range of possible treatment agents have been 
evaluated in the laboratory and in clinical trials.
1
 
 
There has been interest in the use of kappa opioid receptor (KOR) agonists as potential 
pharmacotherapies for cocaine and other psychostimulant abuse,
2-7
 particularly as repeated 
administration of KOR agonists has been shown to prevent, or reduce many of cocaine’s 
behavioural effects.
4,8-10
  Primarily due to the dysphoric effects produced by KOR-agonists, the 
development of a KOR-agonist pharmacotherapy for human use is not straightforward.  For 
example, while enadoline (CI-977), a high efficacy, selective KOR-agonist, appeared to be better 
tolerated in subjects with a history of drug use compared to naive individuals, it still caused some 
dysphoria.
11
  Overall the evidence suggests that higher efficacy KOR-agonists with some additional 
mu opioid receptor (MOR)-agonist activity, such as ethylketazocine (EKC), are more effective in 
reducing cocaine self-administration, and display fewer side effects, than their more KOR-selective 
counterparts such as enadoline and spiradoline.
4,12
  Presumably, the presence of some MOR-agonist 
effects helps attenuate any dysphoria induced by the KOR-agonism.   
In the treatment of opiate abuse, a long-duration of action is of benefit for successful 
treatment agents.  The main pharmacotherapies methadone and buprenorphine (1n), but also 
LAAM, are long acting and their success is at least partly as a result of this property.
13
  Together 
with its reduced efficacy, the slow onset of effects displayed by buprenorphine (1n) appears to 
reduce its abuse potential.  EKC and the other KOR-agonists effective in reducing cocaine self-
administration all have short duration of action.
4
  A strategy for the treatment of cocaine abuse 
 4 
could therefore be the utilization of mixed KOR-agonists/MOR-partial agonists having extended 
duration of action.  Of interest in this regard are the orvinols, a series of opioids displaying a range 
of pharmacological profiles including the long-acting MOR partial agonist 1n.
14
  The orvinols have 
not previously been thoroughly evaluated as KOR-agonists, but it has become clear that a number 
of them do display substantial KOR-efficacy in vivo and that their lack of absolute KOR-selectivity, 
in particular over MOR, makes them of particular interest to this project.  An early example was the 
isopentyl orvinol M320 (5) which was the subject of a detailed pharmacological study by Boura and 
Fitzgerald.
15
  5 shows a KOR/MOR profile similar to that of EKC but it is more potent and very 
much longer acting.  In this manuscript we describe our initial work towards analogues of 5 and 1n 
as potential therapies for cocaine abuse.  There is a particular focus on orvinols having a branched 
chain attached to C20 as these regions (above and away from C6/C7 and below C8) are associated 
with efficacy at KOR.
16,17 
 
Synthesis 
The compounds were prepared using the standard techniques for orvinol synthesis.
14,18,19
  Only one 
significant change has been made to the synthetic route and relates to how and when the N-methyl 
group is replaced with cyclopropylmethyl in series 1.  We have found that this process is most 
reliably performed (simpler and higher yielding) with diisopropyl azodicarboxylate (DIAD) on 
methyl ketone 6 (Scheme 1).  Grignard addition to ketone 8 provided series 1 via 9. Series 2 – 4 
were all synthesised from aldehyde 10, itself prepared from N-cyclopropylnorthebaine,
20
 the initial 
step being the addition of the appropriate Grignard reagent which gave a mixture of diastereomeric 
secondary alcohols, with the major isomer (11a) as shown (Scheme 2).  This major product in each 
case was isolated in sufficient quantity to allow 3-O-demethylation to series 4.  Swern oxidation of 
11a alone or the mixture of diastereomeric alcohols gave ketones 12 that on treatment with 
methylmagnesium bromide and subsequent 3-O-demethylation gave the diastereomeric 3
o
-alcohol 
 5 
series (2).  Reduction of 12 gave the 2
o
 alcohols 11b (major product) and 11a (minor product), with 
3-O-demethylation of 11b giving access to series 3. 
 
Results 
Four series of orvinols were studied.  These were tertiary alcohols having the same relative 
stereochemistry as buprenorphine (1a -1n, Scheme 1), a more limited series of diastereomeric 
tertiary alcohols (2a-2i), secondary alcohols with the same relative stereochemistry as 
buprenorphine (3a-3i) and finally a series of diastereomeric secondary alcohols (4a-4k) (Scheme 2). 
Binding affinities of the new compounds for MOR and KOR were determined by displacement of 
[3H]-diprenorphine binding from C6-rat glioma cells expressing recombinant rat MOR and CHO 
cells expressing recombinant human KOR.  Details of the assay have been described previously.
21
  
Delta opioid receptor (DOR) activity of the new ligands was only determined for the ligands 
progressed to in vivo studies as in no case has DOR activity proved significant in the 
pharmacological profile of orvinol based ligands.  As expected, all of the ligands bound with high to 
very high affinity to both KOR and MOR with little or no selectivity for one receptor over the other 
(Table 1).  If any selectivity was observed, it was for the KOR (e.g. 4b and 4d had 11-fold higher 
affinity for KOR than for MOR).  Affinities for KOR were in the subnanomolar range (0.015 to 
0.22 nM) for all the ligands, with affinities for the MOR in the range 0.029 - 1.0 nM.  Binding 
affinities for five of the ligands (1l, 1m, 2g, 2h, 2i), all synthesized at an earlier time, were 
evaluated in guinea pig brain membranes using established methods.
22
  1a was evaluated in both 
binding assays, providing a reference to enable comparison with the rest of the series.  Affinities 
were lower in the guinea pig brain membrane assay, but confirmed the lack of selectivity, with 
equal affinity for KOR and MOR.  Affinities for 1b and 1c at DOR were determined by 
displacement of [3H]-diprenorphine binding from C6-rat glioma cells expressing recombinant 
DOR.  They bound with high affinity, with Ki values of 0.34 nM and 0.42 nM respectively. 
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The primary in vitro assay used to determine opioid receptor functional activity was the [
35
S]GTPS 
assay which, like the binding assays, was performed on recombinant opioid receptors transfected 
into C6-rat glioma cells (for MOR) and CHO cells (for KOR).  Assays were performed as 
previously described by Traynor and Nahorski.
23
 Agonist efficacy at these opioid receptors was 
determined in comparison to the standard selective agonists DAMGO (MOR), and U69593 (KOR) 
(Table 1).  In this assay buprenorphine (1n) displayed no efficacy at KOR while M320 (5) was a 
very potent, full agonist (91% stimulation).  The new compounds displayed a range of efficacies at 
KOR, from low efficacy partial agonists (e.g. 1a, 1d, 1j, 3a had efficacies from 30 – 49%) to full 
agonists of equivalent efficacy to the standard U69593 (e.g. most of series 4, plus 2c, 2d, 3i 
amongst others).   
 
The majority of ligands displayed lower efficacy at MOR than at KOR; the most extreme examples 
being 3b and 3i which are potent, full agonists at KOR, with no efficacy at MOR.  They proved to 
be potent MOR antagonists shifting the concentration effect curve for the standard agonist DAMGO 
in a parallel fashion giving Ke(MOR) of 0.50 nM and 0.35 nM respectively.  4a was similarly 
selective, but with partial agonist activity at the KOR.  Substantial selectivity in efficacy for KOR 
was seen in a number of other ligands including 1b, 2b, 2c, 2d, 2f, 3g, 4b and 4d.  Within series 1, 
2 and 3 highest MOR efficacy was typically found with the cyclohexylmethyl and closely related 
benzyl side chains.  4h, having a cyclohexylmethyl side chain, also had high efficacy, although in 
this series 4j (having a benzyl group) was only a partial agonist with moderate efficacy.  The two 
ligands, 1b and 1c, evaluated at DOR were both of very low efficacy (2% and 8% stimulation 
respectively). 
 
Five ligands (1l, 1m, 2g, 2h, 2i) were evaluated in the guinea pig ileum (GPI) and mouse vas 
deferens (MVD) isolated tissue assays, instead of [
35
S]GTPS assays (Table 2), using standard 
procedures.
22
  1a and 1n were also tested in these isolated tissue assays to allow meaningful 
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comparison between results from the different assays.  The GPI has both MOR and KOR 
populations and is sensitive to KOR agonist effects, while the MVD has all three types of opioid 
receptor and is particularly sensitive to DOR agonists and least sensitive to KOR agonists.  The n-
propyl analogue (1l) and the diastereomeric n-pentyl analogue (2h) were partial agonists in the GPI 
whereas the other ligands evaluated in this assay were all of higher efficacy.  Thus 1l had lower 
efficacy than its i-propyl isomer 1a and also lower than the bulky t-butyl containing 1n and also 
1m, having the longer n-pentyl chain.  2g, the diastereomer of 1l, was also higher efficacy as was 
the t-butyl containing 2i.  The effects of these ligands in the GPI could not readily be reversed by 
the standard antagonists CTAP and norBNI.  Each of the compounds was found to be an antagonist 
in the MVD with 1a, 1l and 1m displaying some selectivity for MOR.  Antagonist Ke’s at KOR 
were not determined for 2g and 2i as they had demonstrated efficacy in the GPI. 
 
Comparative molecular field analysis (CoMFA) is a technique used to generate a description of a 
3D structure-activity relationship in a quantitative manner, i.e. it is a 3D variant of a quantitative 
structure-activity relationship (QSAR). The output of a CoMFA is a 3D model showing structural 
features of the input data that are likely to affect, beneficially or adversely, the activity of the 
compounds. A CoMFA was used to help identify the regions near C20 that are beneficial or 
detrimental to KOR efficacy and to help confirm the conformation adopted by the different isomeric 
series on binding to the KOR.  All the compounds evaluated in the [
35
S]GTPS assay, including 1n 
and 5, were used to develop the model.  With all compounds overlaid in their lowest energy, C6-
OMe to C20-OH hydrogen bonded conformation (as depicted for 1n in Figure 1) and using the % 
stimulation at KOR data, an R
2
 of 0.911 and cross-validated R
2
 of 0.447 were obtained.  As can be 
seen in Figure 1, the model predicts that for high KOR efficacy there are two areas near to C20 that 
could beneficially be occupied by lipophilic groups, the first is away from C7 and the second is the 
region below C8.  The model also suggests that lipophilic groups closer to C20 are not well 
tolerated, leading to lower KOR efficacy.  Evaluation of alternative conformations about the C7-
 8 
C20 bond (e.g. so that the bulky R group of series 1 and 3 occupies the region below C8) led to 
substantial reductions in R
2
, and in particular the cross-validated R
2
.   
The docking of 1n to the recently published crystal structures of the MOR and KOR opioid 
receptors was examined. The crystal structure
24
 of the KOR was determined in the presence of the 
selective KOR antagonist JDTic and presumably represents the antagonist conformation of the 
receptor.  JDTic is enclosed in a largely hydrophobic pocket with only one direct hydrogen bond to 
the protein. There is a network of water-mediated hydrogen bonds between the ligand and the 
protein. The docked 1n structure overlays the 7-hydroxy-tetrahydroisoquinoline with the 
buprenorphine phenolic hydroxy group making the same interactions as the equivalent group in 
JDTic (Figure 2). There is a hydrogen bond between the protonated nitrogen and the side chain of 
Asp138. The isopropyl group of JDTic fits into and fills a tight pocket formed by Val108, Asn141, 
Trp287 and Tyr320: this interaction is replicated by the cyclopropyl moiety of 1n. The t-butyl group 
makes no specific interactions with the protein, but projects into the large pocket that the 
phenylpiperidine motif of JDTic occupies. 
 
The MOR was crystallised with the irreversible antagonist -FNA present in the binding site,25 a 
ligand with significant structural similarity to buprenorphine. -FNA is covalently bound to the side 
chain nitrogen of Lys233 (Figure 3). The docked 1n structure approximately overlays -FNA but, 
without the covalent restraint, lies a little deeper in the binding site. There is a hydrogen bond 
between the positively charged nitrogen and the sidechain of Asp147. The cyclopropyl moiety 
overlays that of -FNA occupying, but not filling, a small pocket formed by Asn150, Trp293, 
Ile322 and Tyr326. The t-butyl group makes no specific interactions with the protein, but projects 
into the same large pocket occupied by the methyl ester of -FNA. 
 
Two ligands, the i-butyl (1b) and i-pentyl (1c) analogues of buprenorphine (1n) were selected for 
preliminary in vivo evaluation in the para-phenylquinone (PPQ) abdominal stretch assay (Table 
 9 
3).
26
 In this assay PPQ acts as a fairly low intensity nociceptive stimulus such that even partial 
opioid agonists are active as antinociceptives.  These two ligands were chosen as they had the 
desired lower efficacy partial agonist activity at MOR in the [
35
S]GTPS assay coupled with higher 
efficacy at KOR.  As it is difficult to accurately predict the in vivo profile of mixed-action ligands, 
one ligand (1b) was chosen that was substantially biased towards KOR while the other (1c) had a 
more balanced profile.  In the PPQ assay 1b was a potent agonist (ED50 0.02 mg/kg s.c.) that could 
be reversed by norBNI (AD50 6.5 mg/kg s.c.) but only partly reversed by -FNA (a maximum 
reversal of 27% at the highest -FNA dose) (Table 3).  1c was equally potent (0.02 mg/kg s.c.) and 
again could be reversed by norBNI (AD50 2.45 mg/kg s.c.) and partially reversed by -FNA (59% 
reversed at 10 g/brain -FNA). 
 
Discussion 
As predicted, based on earlier work by ourselves and others,
16,17,27
 the N-
cyclopropylmethylnororvinols synthesised and evaluated in this study had very high affinity, but 
little to no MOR/KOR selectivity in binding assays.  Also as predicted, in the [
35
S]GTPS assay 
used to determine the level of agonist activity at each receptor, the majority of the ligands were 
KOR agonists with lower efficacy at the MOR.  Importantly, the [
35
S]GTPS data for the known 
compounds buprenorphine (1n) and M320 (5) were in agreement with previously reported isolated 
tissue data and findings from in vivo studies, with 1n displaying no efficacy at the KOR while 5 
was a very potent, full agonist at this receptor and both displayed partial agonist activity at the 
MOR, such that 1n profiled as a MOR partial agonist, KOR antagonist and 5 as a high efficacy 
KOR agonist with some MOR activity.
14,28
 Similarly, evaluation of 1a in both [
35
S]GTPS and 
isolated tissue assays (Tables 1 and 2) gave results in good agreement, indicating low efficacy at 
each receptor. 
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We have previously proposed that KOR agonist activity can be achieved in orvinol and related 
series through interaction with either a region above and away from C7 (relating to the site occupied 
by the R-group in series 1 and 3) or a region below C8 (relating to the site occupied by the R-group 
in series 2 and 4).
16,17
  The results of the CoMFA analysis performed on the compounds prepared 
for this study are in agreement with this hypothesis.  With all compounds held in their low energy 
H-bonding conformation, an excellent correlation was found between predicted and actual KOR 
efficacy and two regions, corresponding to the two lipophilic sites just described, were highlighted 
as being beneficial to KOR efficacy (Figure 1).  Importantly, this appears to confirm that the 
hydrogen bonded conformation of the orvinols is preserved on interaction with the KOR.   
 
In general the 2
o
 and 3
o
 alcohols having opposite relative stereochemistry to buprenorphine (series 2 
and 4) display higher KOR efficacy than series 1 and 3, which have the same relative 
stereochemistry to buprenorphine.  Substantial differences in efficacy between series was also 
found at the MOR, with series 4 > series 1 > series 2 ≈ series 3.  Comparing the buprenorphine-like 
3
o
 alcohols (1) with their diastereoisomers (2), the results from the [
35
S]GTPS assays indicate that 
those having the same relative stereochemistry as buprenorphine have equal or higher efficacy at 
MOR than their diastereoisomers (2), but that 2 have higher efficacy at KOR, often substantially so.  
This finding was replicated in the GPI assay where buprenorphine (1n) was found to be a MOR 
partial agonist while its isomer (2i) was a potent KOR agonist.  Within the 2
o
 alcohols those with 
the opposite relative stereochemistry (4) to buprenorphine mostly had higher efficacy for both MOR 
and KOR than their diastereoisomers (3).  The 2
o
 alcohols (3, 4) were in general of higher efficacy 
at both MOR and KOR than the 3
o
 alcohols (1, 2). 
 
Within tertiary alcohols (1), KOR efficacy was lowest in those ligands having branching at C21, 
while insertion of one or two methylene units increased KOR efficacy.  So, for example, 1a having 
an isopropyl group was a low efficacy partial agonist (30% relative to U69,593) whereas 1b and 1c 
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(isobutyl and isopentyl containing) were higher efficacy agonists (84% and 69% relative to 
U69,593).  A similar increase in efficacy on going from isopropyl to isobutyl and isopentyl was 
seen in the diastereomeric series of tertiary alcohols (2a versus 2b and 2c) but efficacy at the KOR 
was generally higher for this series than for their diastereomers.  The isopropyl group also led to 
lowest KOR efficacy in both series of secondary alcohols (3a and 4a) though in these series other 
ligands having branching at C21, for example the cyclopentyl in 3d and 4d had significantly higher 
efficacy.  These results are consistent with previous studies in isolated tissue assays with 17-NMe 
orvinols (Series 1, but N-cyclopropylmethyl replaced by N-Me) where it was found that branching 
of the alkyl group at the point of attachment to the carbinol function (i.e. at C21) resulted in lower 
potency and efficacy at the MOR, while in general, MOR and KOR potency and efficacy increased 
with increasing chain length.
17,29
  The results of the CoMFA study provide further support for these 
conclusions with the region adjacent to C21 found to be detrimental to efficacy at the KOR (Figure 
1), appearing to confirm our hypothesis that the loss of KOR efficacy in 1n relative to closely 
related orvinols is due to a methyl group of the t-butyl moiety interacting favourably with the 
antagonist conformation of KOR receptor and/or disfavouring the agonist conformation.
17,27
  
Docking of 1n to the recently published crystal structures of the KOR confirms that the t-butyl 
group accesses a large lipophilic region when the receptor is in an antagonist-bound conformation, 
but does not provide any more detailed information on why buprenorphine is not an agonist at 
KOR. The modeling does shed some light on why the N-cyclopropyl group, and related moieties 
such as allyl, help confer substantial antagonist character to the orvinols and other series; groups of 
this size appear to bind tightly to a pocket formed by Val108, Asn141, Trp287 and Tyr320 in the 
KOR and Asn150, Trp293, Ile322 and Tyr326 in the MOR. 
 
Comparison of 5 and 1c suggests that reducing the 6,14-bridge from etheno to ethano has little or no 
effect on efficacy at MOR but substantially decreases efficacy at KOR.  Previously it has been 
suggested that reduction of bridge leads to some attenuation of MOR intrinsic activity,
14
 though this 
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conclusion was based on in vivo antinociceptive activity and without the benefit of selective 
antagonists or of data from isolated tissue assays.   
 
The in vivo evaluation of 1b and 1c gave results entirely in keeping with the in vitro analysis.  Both 
had substantial KOR agonism with 1c having a greater MOR component than 1b.  While there is 
not a clear dose dependency found in the experiments using -FNA pretreatment, this may simply 
be indicative of the low partial agonist character of these ligands at the MOR meaning we are 
looking at inhibition in vivo of a group of receptors responsible for only part of the activity 
(analgesia) that is the measured end-point. The current in vitro analysis also help rationalise the in 
vivo data that has been reported for a limited number of these compounds previously.
30
  The in vivo 
data was collected on compounds of type 1 with R groups from methyl to butyl (including branched 
isomers) and suggested that compounds with R = n-propyl or larger (up to t-butyl) were MOR 
partial agonists that in some cases had high efficacy KOR agonist activity.
30
  The in vitro data 
generated for the compounds common to these previous studies and the current work (1a, 1b, 1l, 
1n; R = i-propyl, i-butyl, n-propyl and t-butyl) is mostly consistent with these findings with low 
MOR efficacy, but variable KOR efficacy that appears to initially increase with size of the R group 
(e.g. i-propyl → i-butyl, 30 → 84%) before then decreasing again (i-butyl → t-butyl, 84 → 0%).  
The n-propyl analogue (1l) was only evaluated in isolated tissue assays where it was found to be a 
low efficacy agonist in guinea pig ileum (GPI).  The difficulty in reversing the agonist effects of the 
ligands in the GPI by selective antagonists for MOR and KOR (CTAP and norBNI) makes 
commenting on the receptor selectivity of this activity difficult, but is typical of the orvinol series 
and results from their tight, long-lived binding to the receptors and can be indicative of an extended 
duration of action.
17,31
  Differences between the GPI and the cell based [
35
S]GTPS assays may be 
related to the easier access to receptors in the cell homogenates. The activity of these compounds as 
antagonists in the mouse vas deferens (MVD) suggested that all were partial, rather than full, 
agonists.  However, in vivo 1l, having a n-propyl group, appeared to have higher efficacy than the 
 13 
C20 branched chain analogues 1n (t-butyl) and 1a (i-propyl),
30
 contrary to the GPI derived data just 
described. 
 
Conclusions 
The present study confirms the orvinols lack of selectivity in binding to opioid receptors and that 
KOR/MOR agonists of varying efficacy can be obtained from this series.  As predicted, efficacy 
can be controlled by the chain length of the C20 R group and by the introduction of branching or 
ring systems into the chain; a full range of profiles from EKC-like KOR agonists/MOR partial 
agonists (e.g. 1c, 1e), selective KOR agonists (e.g. 3b, 3i, 4a), non-selective agonists (e.g. 1h, 4f) 
and even a ligand with predominant MOR activity (1j) were seen.  Preliminary in vivo evaluation of 
1b and 1c, coupled with the known profiles of 1n and 5a suggests that the [
35
S]GTPS data is 
predictive of the in vivo activity of these ligands.  Compounds have successfully been obtained with 
the targeted profile of potent, moderate to high efficacy KOR agonism combined with potent partial 
agonist activity at the MOR.   
 
Experimental 
Reagents and solvents were purchased from Sigma-Aldrich or Alfa Aesar and used as received. 
Buprenorphine (1n) was supplied by the National Institute on Drug Abuse, Bethesda, Maryland. 
1
H 
and 
13
C NMR spectra were obtained with a Brucker-400-MHz instrument (
1
H at 400 MHz, 
13
C at 
100 MHz); δ in ppm, J in Hz with TMS as an internal standard. ESIMS: microTOF (BRUKER). 
Microanalysis: Perkin-Elmer 240C analyzer. Column Chromatography was performed using 
RediSep pre-packed columns with a Teledyne Isco CombiFlash instrument. Ligands were tested as 
their hydrochloride salts, prepared by adding 5 equivalents of HCl (1 N solution in diethyl ether) to 
a solution of compound in anhydrous methanol. All reactions were carried out under an inert 
atmosphere of nitrogen unless otherwise indicated. All compounds were > 95% pure as determined 
by microanalysis. A representative synthesis for each series is reported here. 
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General procedure A:  Grignard addition 
The Grignard reagents were prepared form the corresponding bromides (5 mmol) by reaction with 
magnesium (182 mg, 7.5 mmol) in anhydrous THF (5 ml) containing a crystal of iodine. The 
Grignard reagents were titrated prior to use by adding 1 ml of the Grignard solution to a flask 
containing 1,10-phenanthroline (~2 mg) in anhydrous THF (2 ml) (purple solution) and titrating 
with 1M 2-butanol (anhydrous) in THF (end point pale yellow solution). 
 
A solution of the appropriate Grignard reagent (1 M in THF, 1.2 ml, 1.2 mmol) was treated 
dropwise at room temperature with a solution of N-cyclopropylmethyl-6,14-endo-
ethanonorthevinone (8) (500 mg, 1.18 mmol) or N-cyclopropylmethyl-6,14-endo-ethanonorthevinal 
(10) (500 mg, 1.22 mmol) in anhydrous toluene (12 ml). After stirring at room temperature for 20 h, 
the reaction was quenched by addition of saturated aqueous ammonium chloride solution (20 ml). 
The phases were separated and the aqueous phase extracted with EtOAc. The combined organic 
phases were washed with saturated aqueous sodium bicarbonate, dried over MgSO4, filtered and 
evaporated in vacuo. The residue was purified by column chromatography over silica gel eluting 
with a gradient from 10% to 30% ethyl acetate in hexane. Rf values are recorded from TLC eluted 
with 30:1:69 ethyl acetate/ammonia solution/hexane. 
 
General Procedure B:  3-O-demethylation with propane thiolate and HCl salt formation 
A solution of the appropriate thevinol (0.25 mmol) in anhydrous HMPA (1 ml) under an inert 
atmosphere was treated with sodium hydride (21 mg, 0.875 mmol) followed by 1-propanethiol (79 
µl, 0.875 mmol). After the addition was complete, the reaction mixture was heated to 120°C and 
stirred for 3 h. On cooling to room temperature, NH4Cl (sat, aq) was added and the mixture 
extracted with diethyl ether. The organic extracts were washed with water (3) and brine. The 
 15 
organic phase was dried (MgSO4) filtered and evaporated to dryness. The residue was purified by 
column chromatography over silica gel. 
 
The HCl salts were prepared by the addition of 2M HCl in diethyl ether (1.2 equiv.) to a solution of 
the orvinol in diethyl ether. The white precipitate which formed was collected by filtration, washed 
with ether and dried under high vacuum. 
 
General Procedure C: Reduction with LiAlH4 
A solution of the ketone (0.215 mmol) in anhydrous THF (7 ml) was added dropwise to a 
suspension of LiAlH4 (20.5 mg, 0.54 mmol) in THF at room temperature. The resulting mixture 
was allowed to stir for 1 hour and then treated carefully with saturated aqueous sodium sulphate 
sulphate solution until all aluminium salts had precipitated. The aluminium salts were removed by 
filtration and washed with Et2O. The filtrate was dried over MgSO4, evaporated to dryness and the 
residue purified by column chromatography over silica gel (30% ethyl acetate, 0.5% NH4OH in 
hexane). 
 
General Procedure D:  Swern oxidation 
A solution of DMSO (170 μl, 2.4 mmol) in anhydrous DCM (5 ml) was added dropwise to a 
solution of oxalyl chloride (93 μl, 1.1 mmol) in DCM (2 ml) at -78C. The resulting solution was 
stirred at -78C for 10 min and then treated dropwise with a solution of the alcohol (1 mmol) in 
DCM (5 ml). The reaction was stirred for a further 15 min before triethylamine (0.7 ml, 5 mmol) 
was added slowly and the resulting solution allowed to warm to room temperature. Water (10 ml) 
was added and the resulting mixture stirred for 10 min. The phases were separated and the aqueous 
phase extracted with DCM. The combined organic extracts were washed with saturated ammonium 
chloride, dried over MgSO4, filtered and the solvent removed under reduced pressure. The residue 
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was purified by column chromatography over silica gel (0.5% NH4OH, 30% ethyl acetate in 
hexane) to afford the product. 
 
 (2R, 5, 6R, 7R, 14)-2-(4,5-epoxy-7,8-dihydro-3,6-dimethoxy-17-cyclopropylmethyl-6,14-
ethano-morphinan-7-yl)-5-methyl-hexan-2-ol (9c) 
Using general procedure A on 8, with isopentyl magnesium bromide, 9c was isolated as a white 
solid (216 mg, 37%). 
1
H NMR (400 MHz, CDCl3)  0.08-0.12 (2H, m), 0.44-0.52 (2H, m), 0.70-
0.83 (2H, m), 0.91 (3H, d), 0.93 (3H, d), 1.01-1.08 (2H, m), 1.19-1.56 (5H, m), 1.34 (3H, s), 1.66 
(1H, dd), 1.74-1.85 (2H, m), 1.90-2.03 (2H, m), 2.19-2.38 (4H, m), 2.64 (1H, dd), 2.79-2.86 (1H, 
m), 2.95-3.01 (2H, m), 3.54 (3H, s), 3.88 (3H, s), 4.42 (1H, s), 5.10 (1H, s), 6.54 (1H, d), 6.70 (1H, 
d). HRMS (ESI
+
) calcd for C31H46NO4 (MH
+
), 496.3421; found 496.3414 (100%). 
 
(2R, 5, 6R, 7R, 14)-2-(4,5-epoxy-7,8-dihydro-3-hydroxy-6-methoxy-17-cyclopropylmethyl-
6,14-ethano-morphinan-7-yl)-5-methyl-hexan-2-ol (1c) 
Using the general procedure B with 9c (50 mg) gave 1c as a yellow solid (47 mg, 98%) 
1
H NMR 
(400 MHz, CDCl3)  0.08-0.12 (2H, m), 0.46-0.50 (2H, m), 0.70-0.83 (2H, m), 0.91 (6H, d), 1.00-
1.08 (2H, m), 1.19-1.26 (1H, m), 1.34 (3H, s), 1.34-1.54 (4H, m), 1.65-1.69 (1H, m), 1.77-1.81 (2H, 
m), 1.90-2.03 (2H, m), 2.18-2.38 (4H, m), 2.66 (1H, dd), 2.79-2.86 (1H, m), 2.95-3.00 (2H, m), 
3.52 (3H, s), 4.42 (1H, s), 5.16 (1H br s), 6.50 (1H, d, J=8.0 Hz), 6.69 (1H, d). HRMS (ESI
+
) calcd 
for C30H44NO4 (MH
+
), 482.3265; found 482.3241 (100%); Anal. (C30H43NO4·HCl·1.5H2O) C, H, 
N. 
 
(1S, 5, 6R, 7R, 14)-1-(4,5-epoxy-7,8-dihydro-3,6-dimethoxy-17-cyclopropylmethyl-6,14-
ethano-morphinan-7-yl)- 2-cyclohexyl-ethan-1-ol (11a: R = cyclohexylmethyl) 
Using general procedure A on 10 with cyclohexylmethylmagnesium bromide gave 11a, isolated as 
a white solid, 89%. 
1
H NMR (400 MHz, CDCl3)  0.09-0.10 (2H, m), 0.46-0.50 (2H, m), 0.68-0.72 
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(1H, m), 0.78-0.89 (3H, m), 0.95-0.98 (1H, m), 1.13-1.28 (5H, m), 1.47-1.53 (4H, m), 1.63-1.71 
(8H, m), 1.83-1.86 (1H, m), 2.00-2.02 (2H, m), 2.21-2.29 (3H, m), 2.32-2.42 (1H, m), 2.58-2.66 
(2H, m), 2.95-3.00 (1H, d), 3.06-3.08 (1H, d), 3.41 (1H, s), 3.86 (3H, s), 4.41 (1H, s), 6.53 (1H, d), 
6.68 (1H, d); HRMS (ESI
+
) calcd for C32H46NO4 (MH
+
), 508.34; found 508.34. 
 
(5, 6R, 7R, 14)-1’-(4,5-epoxy-7,8-dihydro-3,6-dimethoxy-17-cyclopropylmethyl-6,14-
ethano-morphinan-7-yl)-2-cyclohexylethanone (12, R = cyclohexylmethyl) 
Using general procedure D on 11a (R = cyclohexylmethyl) gave 12 (R = cyclohexylmethyl) as a 
white solid (80 mg, 32%). 
1
H NMR (400 MHz, CDCl3)  0.07-0.08 (2H, m), 0.45-0.49 (2H, m), 
0.68-0.78 (2H, m), 0.84-0.95 (2H, m), 1.12-1.16 (1H, m), 1.22-1.35 (4H, m), 1.50-1.51 (1H, m), 
1.54 (3H, s), 1.58-1.68 (5H, m), 1.83-1.85 (1H, m), 1.90-2.00 (1H, m), 2.26-2.35 (3H, m), 2.37-2.38 
(1H, d), 2.47-2.53 (1H, dd), 2.59-2.63 (1H, m), 2.66-2.73 (1H, m), 2.94-2.99 (2H, m), 3.04-3.06 
(1H, d), 3.39 (1H, s), 3.86 (3H, s), 4.44 (1H, s), 6.54 (1H, d), 6.69 (1H, d); HRMS (ESI
+
) calcd for 
C32H44NO4 (MH
+
), 506.33; found 506.33. 
 
 (2R, 5, 6R, 7R, 14)-2-(4,5-epoxy-7,8-dihydro-3,6-dimethoxy-17-cyclopropylmethyl-6,14-
ethano-morphinan-7-yl)-3-cyclohexyl-propan-2-ol  (13: R = cyclohexylmethyl) 
Using procedure A for the addition of methylmagnesium bromide to 12 (R = cyclohexylmethyl), 13 
(R = cyclohexylmethyl) was isolated as a white solid (34 mg, 89%), 
1
H NMR (400 MHz, CDCl3)  
0.08-0.10 (2H, m), 0.47-0.50 (2H, m), 0.69-0.72 (2H, m), 0.90-0.99 (2H, m), 1.04-1.10 (2H, m), 
1.15 (3H, s), 1.20-1.28 (3H, m), 1.56-1-68 (8H, m), 1.74-1.77 (2H, m), 1.85 (1H, m), 1.99-2.03 
(2H, m), 2.18-2.24 (2H, m), 2.26-2.36 (1H, m), 2.58-2.63 (1H, m), 2.78-2.86 (1H, m), 2.96-2.99 
(1H, d), 2.99-2.03 (1H, d), 3.51 (1H, s), 3.87 (3H, s), 4.38 (1H, s), 4.68 (1H, s), 6.53 (1H, d), 6.69 
(1H, d); HRMS (ESI
+
) calcd for C33H48NO4 (MH
+
), 522.36; found 522.36. 
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(2S, 5, 6R, 7R, 14)-2-(4,5-epoxy-7,8-dihydro-3-hydroxy-6-methoxy-17-cyclopropylmethyl-
6,14-ethano-morphinan-7-yl)-3-cyclohexyl-propan-2-ol (2e)  
Using General Procedure B on 13 (R = cyclohexylmethyl) gave 2e as a white solid. 
1
H NMR, 270 
MHz (CDCl3)  0.07-0.11 (2H, m), 0.46-0.50 (2H, m), 0.67-0.81 (2H, m), 0.86-1.30 (10H, m), 
1.55-1.89 (12H, m), 1.94-2.08 (2H, m), 2.14-2.26 (3H, m), 2.34-2.41 (1H, m), 2.55 (1H, dd), 2.76-
2.86 (1H, m), 2.92 (1H, d), 2.99 (1H, d), 3.50 (3H, s), 4.40 (1H, s), 4.71 (1H, s), 6.48 (1H, d), 6.66 
(1H, d); HRMS, m/z for (C32H46NO4) [MH]
+
, calcd- 508.3427, found- 508.3424. Anal. 
(C32H45NO4·HCl·1.5H2O) C, H, N. 
 
(1R, 5, 6R, 7R, 14)-1-(4,5-epoxy-7,8-dihydro-3,6-dimethoxy-17-cyclopropylmethyl-6,14-
ethano-morphinan-7-yl)-3-phenyl-propan-1-ol (11a, R = phenethyl) 
Phenethylmagnesium bromide addition to 10 using general procedure A gave 11a, isolated as a 
white solid (218 mg, 58%). Rf 0.48: 
1
H NMR (400 MHz, CDCl3)  0.08-0.10 (2H, m), 0.46-0.49 
(2H, m), 0.72-0.96 (2H, m), 1.15-1.25 (3H, m), 1.51-1.66 (2H, m), 1.72-1.79 (4H, m), 1.90-2.03 
(2H, m), 2.21-2.35 (4H, m), 2.62-2.69 (3H, m), 2.95-3.06 (2H ,dd), 3.38 (3H, s), 3.86 (3H, s), 4.18 
(1H, m), 4.40 (1H, s), 6.53 (1H, d), 6.68 (1H, d), 7.16-7.30 (5H, m); HRMS (ESI
+
) calcd for 
C33H42NO4 (MH
+
), 516.31; found 516.31. 
 
(5, 6R, 7R, 14)-(4,5-epoxy-7,8-dihydro-3,6-dimethoxy-17-cyclopropylmethyl-6,14-ethano-
morphinan-7-yl)-3-phenyl-propanone (12: R = phenethyl) 
11a, R = phenylethyl (0.36 mmmol) was treated as described in general procedure D. The residue 
was purified by column chromatography using combi flash machine (30% ethyl acetate in hexane) 
to afford 12 (R = phenethyl). Isolated as a white solid (100 mg, 54%) Rf 0.55: 
1
H NMR (400 MHz, 
CDCl3)  0.07-0.09 (2H, d), 0.44-0.49 (2H, m), 0.73-0.76 (1H, m), 1.15-1.32 (2H, m), 1.53-1.57 
(1H, m), 1.56-1.71 (2H, m), 1.99-2.03 (2H, m), 2.23-2.32 (4H, m), 2.59-2.60 (1H, m), 2.70-2.78 
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(2H, m), 2.89-3.08 (5H, m), 3.37 (3H, s), 3.86 (3H, s), 4.43 (1H, s), 6.54 (1H, d), 6.68 (1H, d), 7.14-
7.24 (5H, m);; HRMS (ESI
+
) calcd for C33H40NO4 (MH
+
), 514.30; found 514.30. 
 
 (1R, 5, 6R, 7R, 14)-1-(4,5-epoxy-7,8-dihydro-3,6-dimethoxy-17-cyclopropylmethyl-6,14-
ethano-morphinan-7-yl)-3-phenyl-propan-1-ol (11b: R = phenethyl) 
12 (R = phenylethyl) (100.0 mg, 0.19 mmol), was treated as described in general procedure C to 
give 11b (R = phenethyl).  Isolated as a white solid (86 mg, 86%). Rf 0.51. 
1
H NMR (400 MHz, 
CDCl3)  0.07-0.09 (2H, m), 0.47-0.49 (2H, m), 0.72-0.80 (2H, m), 0.87-0.99 (2H, m), 1.59-1.82 
(5H, m), 1.96-2.04 (2H, m), 2.18-2.34 (5H, m), 2.61-2.72 (2H, m), 2.74-2.82 (1H, m), 2.92-2.99 
(3H, m), 3.54 (3H, s), 3.87 (3H, s), 4.47-4.48 (1H, d), 5.46 (1H, s), 6.54 (1H, d), 6.70 (1H, d), 7.15-
7.18 (1H, m), 7.24-7.28 (4H, m); HRMS (ESI
+
) calcd for C33H42NO4 (MH
+
), 516.31; found 516.31. 
 
(1R, 5, 6R, 7R, 14)-1-(4,5-epoxy-7,8-dihydro-3-hydroxy-6-methoxy-17-cyclopropylmethyl-
6,14-ethano-morphinan-7-yl)-3-phenyl-propan-1-ol (3i) 
11b (R = phenylethyl) (54 .0 mg, 0.10 mmol) was treated as described in general procedure B to 
give 3i. Isolated as a white solid (48 mg, 96%). Rf 0.14; 
1
H NMR, 270 MHz (CDCl3)  0.06-0.09 
(2H, m), 0.45-0.50 (2H, m), 0.64-0.80 (2H, m), 0.82-0.98 (2H, m), 1.58-1.86 (5H, m), 1.91-2.08 
(2H, m), 2.13-2.32 (4H, m), 2.60-2.84 (3H, m), 2.91-3.03 (3H, m),  3.50 (3H, s), 3.81 (1H, t), 4.49 
(1H, s), 5.45 (1H, s), 6.48 (1H, d), 6.67 (1H, d), 7.13-7.32 (5H, m); HRMS, m/z for (C32H40NO4) 
[MH]
+
, calcd- 502.2957, found- 502.2956. Anal. (C32H39NO4·HCl·1.5H2O) C, H, N. 
 
(1S, 5, 6R, 7R, 14)-1-(4,5-epoxy-7,8-dihydro-3-hydroxy-6-methoxy-17-cyclopropylmethyl-
6,14-ethano-morphinan-7-yl)-3-phenyl-propan-1-ol (4k) 
11a (R = phenethyl) was treated as described in General Procedure B to give 4k. 
1
H NMR (400 
MHz, CDCl3)  0.08-0.09 (2H, m), 0.45-0.50 (2H, m), 0.66 (1H, m), 079 (1H, m), 1.12-1.13 (1H, 
m), 1.39-1.48 (1H, m), 1.52-1.57 (2H, m), 1.63-1.67 (1H, d), 1.70-1.80 (4H, m), 1.90-1.99 (3H, m), 
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2.19-2.38 (5H, m), 2.60-2.70 (3H, m), 2.85 (1H, m), 2.93-2.98 (1H, d), 3.04-3.05 (1H, d), 3.35 (3H, 
s), 4.41 (1H, s), 6.49 (1H, d), 6.67 (1H, d), 7.16 (1H, m), 7.16-7.30 (5H, m); HRMS (ESI
+
) calcd for 
C32H40NO4 (MH
+
), 502.2957; found 502.3002. Anal. (C32H39NO4.HCl.0.5H2O) C, H, N. 
 
Molecular Modeling.  CoMFA - All the modelling was carried out using the Sybyl-X 1.0 
molecular modelling environment from Tripos Inc. The molecules were built, assigned with 
Gasteiger-Huckel charges and minimised using the MMFF94s force field. The CoMFA analysis 
was carried out as per the instructions in the Sybyl-X 1.0 documentation. Docking - The 4DJH 
crystal structure of the KOR and the 4DKL crystal structure of the MOR were prepared for docking 
work by running them through the Protein Preparation Wizard tool of the Schrödinger software. 1n 
was built using the Schrödinger software. GOLD was used to dock 1n into both prepared protein 
structures. The binding site was defined as a sphere of 5Å radius centred on the centroid of the 
crystal structure ligand with the requirement that the centroid of the docked ligand lie within this 
sphere. Water molecules in the crystal structure were left in place. 
 
Supporting Information. Full experimental details. This material is available free of charge via the 
Internet at http://pubs.acs.org 
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Table 1: Binding affinities
a
 of ligands to opioid receptors and stimulation of [
35
S]GTPS bindingb 
to CHO-KOR and C6-MOR membranes. 
 R Ki/nM – MOR Ki/nM - KOR EC50/nM,     % stim’ 
MOR 
EC50/nM,       % stim’ 
KOR 
      
1a iPr 0.15±0.013 0.051±0.024 2.1±1.4,        12±4.4 0.083±0.048,   30±5.3 
1a
c iPr 0.60±0.05 0.40±0.20   
1b ibutyl 0.20±0.037 0.092±0.025 1.2±0.56,      14±1.0 0.057±0.029,   84±4.1 
1c ipentyl 0.22±0.018 0.060±0.013 0.19±0.049,  33±7.6 0.071±0.027,   69±5.1 
1d cpentyl 0.21±0.042 0.074±0.024 2.8±1.7,        25±3.7 0.068±0.045,   46±4.9 
1e cpentylmethyl 0.29±0.063 0.069±0.019 0.56±0.12,    38±0.35 0.011±0.0033, 93±1.2 
1f cpentylethyl 0.62±0.17 0.12±0.019 2.9±0.51,      56±4.7 0.027±0.0067, 82±5.3 
1g chexyl 0.21±0.069 0.10±0.033 0.43±0.10,    35±2.8 0.031±0.0061, 53±0.22 
1h chexylmethyl 0.34±0.12 0.051±0.016 1.7±0.86,      63±5.7 0.017±0.0012, 75±1.6 
1i chexylethyl 1.0±0.14 0.18±0.022 4.8±1.5,        43±4.6 0.041±0.035,   89±1.7 
1j benzyl 0.15±0.036 0.082±0.025 1.3±0.98,      75±8.6 0.071±0.011,   44±6.6 
1k phenethyl 0.32±0.067 0.065±0.022 4.9±3.0,        47±8.6 0.016±0.011,   89±6.9 
1l
c nPropyl 0.90±0.20 1.2±0.10 N.D. N.D. 
1m
c nPentyl 2.4±1.0 4.7±0.10 N.D. N.D. 
1n tButyl 0.19±0.018 0.067±0.021 0.27±0.094,  18±0.99 -,                      0 
2a ipropyl 0.091±0.011 0.11±0.024 1.27±0.72,    11±1.1 0.46±0.13,       53±2.6 
2b ibutyl 0.19±0.036 0.11±0.024 0.85±0.59,   7.6±1.7 0.18±0.078,     89±4.0 
2c ipentyl 0.21±0.099 0.15±0.044 0.43±0.098,  25±1.3 0.16±0.084,     96±11 
2d cpentyl 0.18±0.048 0.15±0.037 1.0±0.66,     9.3±2.1 0.083±0.016,   95±5.2 
2e chexylmethyl 0.37±0.12 0.22±0.057 0.72±0.015,  46±1.8 0.31±0.17,       87±1.5 
2f chexylethyl 0.47±0.21 0.16±0.012 2.50±0.98,   8.5±1.8 0.46±0.15,       72±2.4 
2g
c
 nPropyl 1.3±0.0 2.0±0.50 N.D. N.D. 
2h
c
 nPentyl 2.7±0.85 5.5±0.90 N.D. N.D. 
2i
c
 tButyl 0.40±0.05 0.50±0.10 N.D. N.D. 
3a ipropyl 0.33±0.16 0.067±0.011 1.0±0.41,     6.9±3.8 0.63±0.22,      49±3.1 
3b ibutyl 0.054±0.013 0.059±0.014 -,                  0
d
 0.17±0.045,      89±3.9 
3c ipentyl 0.031±0.0086 0.033±0.011 1.5±0.99,     39±4.8 0.042±0.0027,  89±2.0 
3d cpentyl 0.31±0.23 0.078±0.015 0.60±0.057,  11±1.2 0.29±0.12,       71±5.4 
3e chexyl 0.15±0.035 0.090±0.042 0.26±0.063,  48±3.8 0.053±0.0088, 78±1.9 
3f chexylmethyl 0.043±0.016 0.015±0.0043 0.56±0.098,  45±4.5 0.19±0.037,      81±4.6 
3g chexylethyl 0.060±0.021 0.019±0.0030 2.0±0.45,      23±1.6 0.24±0.027,     94±9.3 
3h benzyl 0.038±0.018 0.020±0.0066 0.32±0.11,   41±2.4 0.077±0.039,    87±8.7 
3i phenethyl 0.029±0.0035 0.025±0.0039 -,                   0
d
 0.052±0.020,   109±8.2 
4a ipropyl 0.88±0.19 0.16±0.079 -,                   0 0.035±0.018,   59±7.2 
4b ibutyl 0.68±0.20 0.057±0.025 0.48±0.24,    20±2.0 0.013±0.0092, 107±7.3 
4c ipentyl 0.12±0.0074 0.067±0.023 0.16±0.059,  65±2.0 0.0061±0.002, 113±3.3 
4d cpentyl 1.0±0.48 0.086±0.048 0.29±0.12,    35±35 0.020±0.080,  104±12 
4e cpentylmethyl 0.36±0.067 0.086±0.040 0.16±0.060,  80±3.3 0.007±0.0007, 103±3.9 
4f cpentylethyl 0.49±0.058 0.062±0.017 0.16±0.026,  83±7.8 0.0077±0.0045, 95±8.1 
4g chexyl 0.41±0.14 0.12±0.0082 0.12±0.0070, 73±8.1 0.0098±0.003, 102±6.2 
4h chexylmethyl 0.27±0.12 0.12±0.028 0.094±0.029, 91±9.3 0.029±0.015,  108±1.9 
4i chexylethyl 0.23±0.17 0.086±0.016 0.20±0.10,    34±2.9 0.047±0.003,   83±6.7 
4j benzyl 0.030±0.0041 0.041±0.0060 0.23±0.13,    45±4.0 0.076±0.043,   63±7.3 
4k phenethyl 0.029±0.0058 0.047±0.0054 21.0±17.5,   7.5±2.0 0.73±0.58,       58±4.9 
5 iPentyl
e
 0.18±0.068 0.082±0.019 1.0±0.42,    34±3.2 0.051±0.022,   91±3.7 
EKC   0.39±0.11 4.4±2.5,        26±1.0 2.2±0.66,      93±1.3 
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a
Ki (nM) versus [
3
H]diprenorphine, values are an average ± SEM from three separate experiments.  
b
Percent maximal stimulation (% stim) with respect to the standard agonists DAMGO (MOR) and 
U69,593 (KOR), values are an average ± SEM from three separate experiments, N.D. not 
determined. 
 c
Binding to Hartley guinea pig membranes, Ki (nM) versus [
3
H]DAMGO (MOR) and 
[
3
H]U69,593 (KOR).  
d 
3b Ke (versus DAMGO) 0.50±0.08 nM, 3i Ke (versus DAMGO) 0.35±0.11.  
e
C6-C14 etheno bridged. F Affinities for 1b and 1c at DOR were determined by displacement of 
[3H]-diprenorphine binding from C6-rat glioma cells expressing recombinant DOR; Ki values were 
0.34±0.07 nM and 0.42±0.18 nM respectively. Efficacy at DOR was 1b:2.3±1.3%, EC50 not 
determined and 1c: 7.9±1.7%;  EC50 values not determined 
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Table 2: Agonist activity (IC50/nM) in the guinea pig ileum (GPI) and antagonist activity (Ke/nM) 
in the mouse vas deferens (MVD). 
  GPI Ke (nM)
a
 MVD
e
 
         IC50 (nM) CTAP norBNI Ke (MOR) Ke (KOR) Ke (DOR) 
1a 
1l  
1m  
1n  
2g  
2h  
2i  
iPr 
nPr 
nPent 
tBu 
nPr 
nPent 
tBu 
0.52  0.49 
P.A.
c
 
12.3  2.1 
8.1  3.6 
0.49±0.31 
P.A. 
2.0±1.4 
N.R.
b
 
N.D.
d
 
N.R. 
N.R 
N.R. 
N.D. 
N.R. 
N.R. 
N.D. 
N.R. 
N.R 
0.71±0.07 
N.D. 
1.8±1.33 
0.0340.004 
0.0070.0002 
0.0040.001 
- 
0.028±0.003 
0.02±0.006 
0.043±0.009 
0.370.21 
0.200.12 
0.110.04 
- 
- 
0.01±0.002 
- 
0.900.32 
0.160.03 
0.060.02 
- 
0.31±0.08 
0.35±0.06 
15±5.9 
a
Ke (nM) of the selective antagonists norBNI (KOR) and CTAP (MOR) versus test compound.  
b
N.R. – the antagonists did not reverse the activity of the test compound.  cPartial agonist with 
maximum inhibition of twitch of 30 – 50%.  dN.D. Not determined.  eAntagonist Ke (nM) of the test 
compound versus the standard agonists DAMGO (MOR), U69,593 (KOR) and DPDPE (DOR).  
Values are from two experiments each carried out in triplicate 
 
 
Table 3: Antinociceptive activity in the PPQ induced abdominal stretch assay 
  Reversal by selective opioid antagonists:  AD50 or % reversal 
 ED50, mg/kg s.c. -FNA, g/brain i.c.v (MOR) norBNI, mg/kg s.c. (KOR) 
1b 0.02 (0.01 – 0.03) 15% at 1, 5% at 10, 27% at 30 6.5 (2.6 – 16) 
1c 0.02 (0.01 – 0.04) 14% at 3, 59% at 10, 12% at 30 2.5 (0.53 – 11.4) 
Methods as described previously (ref 26) 
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Figure 1: Two views of the areas, predicted by COMFA analysis, where interaction with a 
lipophilic group would be beneficial for KOR activation (shown in green) and where interaction 
with a lipophilic group would be detrimental to efficacy (shown in yellow).  
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Figure 2: The KOR with the protein in green, the crystal structure ligand (JDTic) in cyan and the 
docked buprenorphine (1n) in pink. The hydrogen bond between the docked ligand and Asp138 is 
shown as the black dashed line. 
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Figure 3: The MOR with the protein in green, the crystal structure ligand (-FNA) in cyan and the 
docked buprenorphine (1n) in pink. The hydrogen bond between the docked ligand and Asp147 is 
shown as the black dashed line. 
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Scheme 1: (i) DIAD, CH3CN, reflux then pyridine hydrochloride, EtOH, r.t. 
(ii) cyclopropylmethyl bromide, NaHCO3, DMF, 90
o
C  (iii)  
RMgBr, THF, toluene, r.t.  (iv) NaSPr, HMPA, 120
o
C. 
 
 
 33 
 
 
 
Scheme 2: (i) acrolein, toluene, reflux  (ii) H2, Pd/C, EtOH, 50psi, 50
o
C  (iii) RMgBr, THF, 
toluene, r.t.  (iv) (COCl)2, NEt3, DMSO, CH2Cl2, -78
o
C  (v) MeMgBr, THF, r.t.  (vi) NaSPr, 
HMPA, 120
o
C  (vii) LiAlH4, THF, r.t. 
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